dermatofibrosarcoma protuberans, CEL/HES, MDS/MPN, systemic mastocytosis
Haematology · 2018–2018
1decision
1medicine
0carried consumer input
0individual submissions
No submission for this condition has carried consumer input, including the one made since the comments facility came into use.
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| imatinib Continuing treatment of rare diseases including dermatofibrosarcoma protuberans, chronic eosinophilic leukaemia or hypereosinophilic syndrome, myelodysplastic… | Jul 2018 | Recommended with restriction | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.